Abstract
Of 69 clinical isolates of Finegoldia magna tested, 36% presented high-level MICs of erythromycin (>256 μg/ml), harboring erm(A) (n = 20) or erm(B) (n=5). Of nine isolates exhibiting an inducible resistance phenotype to macrolides-lincosamides-streptogramins B, four (44%) were susceptible with a potential risk of treatment failure due to emergence of resistant mutants.
Keywords:
F. magna; GPAC; MLS; anaerobes; clindamycin; erm(A); erm(B).
Copyright © 2020 Elsevier Ltd. All rights reserved.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anti-Bacterial Agents / pharmacology
-
Bacterial Proteins / genetics
-
DNA, Bacterial / genetics
-
Drug Resistance, Multiple, Bacterial / genetics*
-
Female
-
Firmicutes / drug effects*
-
Firmicutes / genetics*
-
Firmicutes / isolation & purification
-
Gram-Positive Bacterial Infections / diagnosis
-
Gram-Positive Bacterial Infections / microbiology
-
Humans
-
Lincosamides / pharmacology*
-
Macrolides / pharmacology*
-
Male
-
Methyltransferases / genetics*
-
Middle Aged
-
RNA, Ribosomal, 23S / genetics
-
Streptogramins / pharmacology*
-
Young Adult
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
DNA, Bacterial
-
Lincosamides
-
Macrolides
-
RNA, Ribosomal, 23S
-
Streptogramins
-
Methyltransferases
-
rRNA (adenosine-O-2'-)methyltransferase